|In adult patients with active PsA and frequent serious infections who are both OSM- and biologic treatmentâ€“naive,| |
|2. Start an OSM over a TNFi biologic (PICO 64)|Moderate (33, 120)|
|Strong recommendation supported by moderate-quality evidence, including a black box warning against the use of a TNFi biologic with regard to increased risk of serious infection.| |
|3. Start an IL-12/23i biologic over a TNFi biologic (PICO 65)|Very low (33)|